Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients

Inclusion Criteria: * Participant 10 to 17 years old inclusive with weight \> 40kg. * Participant 18 to 65 years old inclusive; * Participants with relapsing multiple sclerosis * Participants never used fingolimod before enrollment * Subjects with Expanded Disability Status Scale (EDSS) score of 0 - 6.0 (inclusive) at Screening Exclusion Criteria: * Participants with certain cardiovascular conditions and/or findings in the screening ECG. * Diagnosis of macular edema during screening visit. * Increased risk for opportunistic infections * Participants with known active malignancies. * Participants who have been treated with teriflunomide within 3.5 months prior to baseline, except if active washout. * Participants with severe active infections, active chronic infection. * Participants with severe liver impairment. * Pregnant confirmed by a positive pregnancy test or nursing (lactating) women.